Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
(HealthDay News) – For patients with dysglycemia and at high risk of cardiovascular events, supplementation with omega 3 (n-3) fatty acids does not reduce the rate of cardiovascular events.
Jackie Bosch, from McMaster University and Hamilton Health Sciences in Canada, and colleagues from the Outcome Reduction with Initial Glargine Intervention trial, randomized 12,536 adults (mean age, 63.5 years) with cardiovascular risk factors and impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to a 1g capsule containing at least 900mg n-3 fatty acids or placebo, in addition to either insulin glargine or standard care.
During a median of 6.2 years of follow-up, the researchers found that the incidence of death from cardiovascular causes was not significantly different for those receiving n-3 fatty acids or standard care (9.1 vs. 9.3%; P=0.72). Supplementation with n-3 fatty acids had no significant effect on the rates of major vascular events, death from any cause, or death from arrhythmia. Among patients receiving n-3 fatty acids, triglyceride levels were reduced by 14.5mg/dL more than among those receiving placebo (P<0.001), with no significant impact on other lipids. The rates of adverse effects were similar between the groups.
“Daily supplementation with 1g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events,” the authors write.
The study was supported by Sanofi and study drugs were provided by Pronova BioPharma Norge; several authors disclosed financial ties to pharmaceutical companies, including Sanofi.
